Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes-Reference-Cited by-同舟云学术

Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes

Published:2021-05-25 Issue: Volume: Page:
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Wu Ya-li,Xue Ya-ru,Guo Zi-tao,Chen Zhen-dong,Ge Xin-yu,Zhong Da-fang,Diao Xing-xing

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.nature.com/articles/s41401-021-00692-7.pdf

Reference28 articles.

1. Shi Y, Zhang S, Hu X, Feng J, Ma Z, Zhou J, et al. Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation. J Thorac Oncol. 2020;15:1015–26.

2. Liu XY, Guo ZT, Chen ZD, Zhang YF, Zhou JL, Jiang Y, et al. Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacol Sin. 2020;41:1366–76.

3. Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmcol. 1999;56:1329–39.

4. Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev. 2010;62:1238–49.

5. Williamson BL, Purkayastha S, Hunter CL, Nuwaysir L, Hill J, Easterwood L, et al. Quantitative protein determination for CYP induction via LC-MS/MS. Proteomics. 2011;11:33–41.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy Evaluation of Adjuvant Therapeutic Drugs Against Early and Middle Stage Non‐Small Cell Lung Cancer Organoids;Advanced Therapeutics;2024-07-18

2. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations;Frontiers in Immunology;2024-05-07

3. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review;Medicine;2023-12-29

4. Significant benefit of high-dose furmonertinib in the treatment of leptomeningeal metastases from non-small-cell lung cancer with EGFR ex19Del mutation: Two case reports and a literature review;2023-11-21

5. Mechanism of metformin regulation in central nervous system: Progression and future perspectives;Biomedicine & Pharmacotherapy;2022-12